You are here

VELUM INC

Company Information
Address
254 UPLAND RD
CAMBRIDGE, MA 02140-3605
United States



Information

UEI: Y5DJXLQZL6F8

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Protease Stable N-Terminally Modified Therapeutic Peptides

    Amount: $367,389.00

    PROJECT SUMMARY Peptide therapeutics combine high potency and selectivity, and engender fewer side effects than traditional small molecules. This has fueled interest in peptides filling the gap betwee ...

    STTRPhase I2022Department of Health and Human Services National Institutes of Health
  2. Triagonist Peptide Therapeutics for Neuroprotection

    Amount: $259,613.00

    Project Summary Morbidity associated with neuronal degeneration and dysfunction poses an increasing public health burden. Among the wide range of etiologies that result in neuronal dysfunction, includ ...

    STTRPhase I2021Department of Health and Human Services National Institutes of Health
  3. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    Amount: $1,705,507.00

    Project Summary There is a world-wide “twin epidemic” of obesity and Type 2 Diabetes (T2D), with an urgent need to find effective new drug treatments for inducing weight loss. Stable derivatives o ...

    STTRPhase II2021Department of Health and Human Services National Institutes of Health
  4. Rapid High-Fidelity Assembly of Challenging Peptide Sequences

    Amount: $225,000.00

    PROJECT SUMMARY Peptide therapeutics combine high potency and selectivity with fewer side effects than traditional small moleculesThis has fueled interest in peptides filling the gap betweenbiologicsa ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  5. Design of Protease Stable Therapeutic Peptides by Non-Perturbative Modification

    Amount: $222,678.00

    PROJECT SUMMARY! Peptide therapeutics combine high potency and selectivityand engender fewer side effects than traditional small moleculesThis has fueled interest in peptides filling the gap between ` ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  6. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    Amount: $225,000.00

    There is a world wide twin epidemic of obesity and TypeDiabetesT Dwith an urgent need to find effective new drug treatments for inducing weight lossStable derivatives of the endogenous glucoregulatory ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government